Korean biopharma developing autoimmune and eye-disease antibody drugs, including an FcRn inhibitor licensed to global partners.
Korean biopharma developing autoimmune and eye-disease antibody drugs, including an FcRn inhibitor licensed to global partners.
Partners Immunovant and Harbour BioMed, not Hanall, run the late-stage trials for batoclimab, so Hanall relies on upfront payments, milestones and royalties from them while its Korean branded-generic drugs pay current costs.
Moat: narrow (IP / patents). Licensed FcRn-inhibitor antibody drug now in global late-stage trials via partners.
Headquarters: Seoul, South Korea · Founded: 1973 · Employees: 315
Size Hanall Biopharma (009420.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $2.01B, the 140th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩52,300 on 18 Nov 2026.
Performance Over six months the shares gained 12.5%, against -5.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 5.0% over the last twelve months (peer median +11.1%); the operating margin is 3.0% (peer median 22.2%).
Valuation It trades at 16.6× enterprise value to sales against a peer median of 4.8× (2nd most expensive of 20).
Capital Return on invested capital runs 5.5 points below its cost of capital (7.6% WACC).
Next results Next results expected around 20 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩162B | ₩155B | ₩139B | ₩135B | ₩110B |
| Revenue growth | — | +12% | +3% | +23% | — |
| Gross profit | ₩83.0B | ₩79.1B | ₩71.7B | ₩73.7B | ₩60.6B |
| EBITDA | ₩8.00B | ₩1.94B | ₩3.35B | ₩4.99B | ₩4.56B |
| Net income | -₩22.1B | -₩5.56B | -₩1.80B | ₩3.51B | ₩251M |
| Free cash flow | -₩7.82B | -₩3.29B | ₩7.72B | ₩27.2B | ₩22.4B |
| Capital expenditure | ₩11.5B | ₩14.1B | ₩23.1B | ₩9.20B | ₩7.68B |
| Total debt | ₩39.9B | ₩31.9B | ₩1.45B | ₩1.29B | ₩1.31B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Hanall Biopharma 009420.KS | $2.01B | +12% | +5% | 3% | 16.6× | n/a |
| argenx SE Sponsored ADR ARGX | $59.1B | +17% | +71% | 29% | 10.3× | 11.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 009420.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +25.9% | +0.3% | highest of 21 |
| 6-month return | +12.5% | -5.5% | 5th highest of 21 |
| Distance from 52-week high | -28.4% | -28.7% | 11th highest of 21 |
| Revenue growth (TTM) | +5.0% | +11.1% | 6th lowest of 20 |
| Operating margin | 3.0% | 22.2% | 3rd lowest of 20 |
| EV / Sales | 16.6× | 4.8× | 2nd most expensive of 20 |
| ROIC minus cost of capital | -5.5 pp | +1.6 pp | 4th lowest of 20 |
| Net debt / EBITDA | 2.1× | 0.7× | 2nd most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | 16.6× | n/a | n/a |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 2.8× | -2.0% | +341.1% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | 30.9× | n/a | n/a |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 2.4× | 1.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 3.2× | 5.1% | +6.4% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 6.2× | 26.3% | +20.9% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 3.3× | -4.7% | +10.6% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 11.8× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 1.4× | -10.5% | +40.3% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 8.4× | 3.2% | +15.7% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 7.3× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 2.0× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 1.5× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 10.1× | n/a | n/a |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 4.0× | -11.0% | +37.6% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 6.3× | 20.1% | +6.2% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 5.5× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 4.8× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 3.4× | -1.2% | +16.7% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 8.6× | n/a | n/a |